Arizona Tribune - AimwellBio Reports Strong Early Demand From Hospital Systems and Researchers as FHIN Founding Cohort Takes Shape

Founding Cohort Gains Traction With Clinical Research Teams

John Morgan, who led the initial hospital engagement, confirmed that the meeting exceeded expectations. The hospital system in question is now evaluating a potential phased onboarding of its research division as the first step toward potential institutional participation in the FHIN contributor network. Additional meetings with hospitalists and clinical researchers are scheduled throughout this week, with further details to be announced as onboarding agreements are formalized.

Early feedback from physicians and researchers has centered on a consistent challenge: they cannot reliably trust AI-generated outputs and do not have the time or infrastructure to independently verify them.

This is the exact gap AimwellBio was built to address.

Why the Medical Community Is Responding

The healthcare industry is experiencing a structural trust challenge driven by the rapid adoption of artificial intelligence tools that were not originally designed for clinical or regulatory decision-making. General-purpose AI models - commonly used to draft content and summarize information - are increasingly being applied to generate drug research summaries, regulatory analyses, clinical trial interpretations, and executive-level intelligence across the pharmaceutical and healthcare landscape.

The challenge is that these models can produce hallucinations - including fabricated citations, inaccurate study interpretations, and incorrect clinical details - often presented with high confidence.

Studies and surveys published between 2024 and 2025 have indicated that a significant portion of physicians have encountered AI-generated inaccuracies in medical contexts, with many expressing concern about the potential for downstream clinical impact. Additional academic research has suggested that AI-generated inaccuracies may be presented with increased linguistic confidence, making them more difficult to detect.

For physicians and researchers operating under regulatory scrutiny, malpractice exposure, and fiduciary obligation, the current environment presents a growing risk. They require intelligence that is verifiable, traceable, and decision-ready - not probabilistic outputs that require manual validation.

Understanding RegTech - And Why It Matters Now

Regulatory Technology (RegTech) refers to the use of technology to monitor, manage, and support compliance with evolving regulatory frameworks. While financial services led early adoption, healthcare is rapidly emerging as a major RegTech growth sector, driven by increasing oversight of AI usage, data governance requirements, and global regulatory complexity across agencies such as the FDA, EMA, and PMDA.

AimwellBio operates at the intersection of RegTech and decision intelligence - applying regulatory technology to the biopharma decision chain.

The company's platform, AIMWELL Cortex, ingests signals from multiple independent data sources, verifies outputs against primary references, assigns confidence scoring, and delivers structured intelligence to stakeholders including executives, regulatory teams, researchers, and clinicians.

For example, a clinical researcher tracking oncology developments may receive a verified intelligence brief consolidating FDA updates, clinical trial readouts, and peer-reviewed findings - each traceable to primary source material.

Cortex includes a dedicated hallucination mitigation layer designed to identify and filter unverifiable AI-generated claims before they enter the decision workflow. If a claim cannot be sufficiently validated, it is flagged or excluded from output delivery.

The platform also builds institutional memory over time, enabling organizations to retain validated knowledge across personnel changes and operational transitions.

Aimwell Partners intends to establish a leadership position within healthcare RegTech by developing a verified intelligence infrastructure layer for the industry.

FHIN: Building a Verified Biopharma Intelligence Network

The Federated Health Intelligence Network (FHIN) is a contributor-driven data network designed to support the creation of a highly verified biopharma intelligence dataset.

Unlike traditional data aggregation models that rely on scraping or third-party sourcing, FHIN requires submitted data to pass automated quality scoring and human review processes prior to inclusion. Contributors - including researchers, clinicians, institutions, and pharmaceutical organizations - earn platform credits based on the quality and utilization of their contributions.

The network is designed to create a reinforcing data cycle: increased verified data improves intelligence outputs, which attracts additional users and contributors, further strengthening the dataset.

In the near term, FHIN provides two primary benefits:

1. A mechanism for researchers and clinicians to contribute verified insights while receiving platform-based value in return

2. An independent verification layer to support decision-making across the healthcare and biopharma ecosystem

The founding cohort is intentionally limited. Early participants are expected to contribute to the development of data standards, quality frameworks, and governance structures that will shape the network over time.

Expanding Reach Through Scientific and Medical Associations

In parallel with FHIN cohort development, Aimwell Partners is pursuing memberships in scientific and medical associations to expand engagement with clinical and research communities.

These memberships are intended to:

• Strengthen credibility within established professional networks

• Create direct engagement channels with potential FHIN contributors

• Position the company within ongoing discussions around AI governance and regulatory standards in healthcare

Specific memberships will be announced as they are finalized.

What the Early Feedback Is Telling Us

A consistent theme across recent engagements is that physicians and researchers are seeking solutions that reduce the burden of verifying large volumes of fragmented information.

They are tracking regulatory updates, clinical trial activity, competitive pipelines, safety signals, and emerging research - often using tools that require additional validation steps.

Cortex is designed to address this challenge by continuously monitoring relevant signals, delivering verified intelligence, and structuring outputs based on user roles.

For individual practitioners, this may include periodic intelligence briefings with source traceability. For institutions, it enables the development of a persistent intelligence layer that compounds over time.

The company plans to provide further updates as evaluation processes advance and participation in the FHIN founding cohort expands.

Join the Founding Cohort or Nominate a Contributor

AimwellBio is actively engaging hospital systems, researchers, clinicians, scientists, and medical associations interested in participating in the FHIN founding cohort.

Submissions, referrals, and introductions are welcomed.

Contact: [email protected]

Learn more:
aimwellbio.com/understand
aimwellbio.com/fhin
aimwellbio.com/investors
aimwellbio.com

About Aimwell Partners Inc.
Aimwell Partners Inc. (OTCID:AIMN) is the parent company of AimwellBio, a verified intelligence platform for the healthcare and biopharmaceutical industry. The company's core system, AIMWELL Cortex, provides signal monitoring, validation workflows, institutional knowledge retention, and structured intelligence delivery for biotechnology companies, pharmaceutical organizations, healthcare providers, research institutions, and investment teams.

The Federated Health Intelligence Network (FHIN) is the company's contributor-driven data initiative focused on building a verified biopharma intelligence ecosystem.

Media Contact: John Morgan [email protected]

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include, but are not limited to, expectations regarding product capabilities, onboarding processes, market adoption, association memberships, and competitive positioning.

AimwellBio does not provide medical advice, regulatory guidance, legal counsel, or investment recommendations. The platform is not a registered medical device, regulatory authority, or investment advisor.

Referenced market observations and research are derived from publicly available academic and industry sources, including publications associated with The Lancet Digital Health, Frontiers in Digital Health, MIT-affiliated research, JAMA, and ECRI.

Investors are encouraged to conduct independent due diligence and consult qualified advisors prior to making investment decisions.

SOURCE: Aimwell Partners

View the original press release on ACCESS Newswire

D.Lopez--AT